1. Bögeholz, N. et al. Spotlight on S-ICDTM therapy: 10 years of clinical experience and innovation. Europace21, 1001–1012 (2019).
2. Burke, M. C. et al. 1-Year Prospective Evaluation of Clinical Outcomes and Shocks: The Subcutaneous ICD Post Approval Study. JACC Clin Electrophysiol6, 1537–1550 (2020).
3. Willy, K. et al. Performance of the entirely subcutaneous ICD in borderline indications. Clin Res Cardiol109, 694–699 (2020).
4. Willy, K. et al. The role of entirely subcutaneous ICDTM systems in patients with dilated cardiomyopathy. J Cardiol75, 567–570 (2020).
5. Willy, K. et al. Outcome differences and device performance of the subcutaneous ICD in patients with and without structural heart disease. Clin Res Cardiol109, 755–760 (2020).
6. Willy, K. et al. The entirely subcutaneous ICDTM system in patients with congenital heart disease: experience from a large single-centre analysis. Europace21, 1537–1542 (2019).
7. Knops, R. E. et al. Subcutaneous or Transvenous Defibrillator Therapy. N Engl J Med383, 526–536 (2020).
8. Younis, A. et al. Predicted benefit of an implantable cardioverter-defibrillator: the MADIT-ICD benefit score. Eur Heart J (2021) doi:10.1093/eurheartj/ehaa1057.
9. Hohnloser, S. H. et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med351, 2481–2488 (2004).
10. Colquitt, J. L. et al. Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure: systematic review and economic evaluation. Health Technol Assess18, 1–560 (2014).
11. Jukema, J. W. et al. Prophylactic Use of Implantable Cardioverter-Defibrillators in the Prevention of Sudden Cardiac Death in Dialysis Patients. Circulation139, 2628–2638 (2019).
12. Køber, L. et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. N Engl J Med375, 1221–1230 (2016).
13. Moss, A. J. et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med346, 877–883 (2002).
14. Moss, A. J. et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med361, 1329–1338 (2009).
15. Moss, A. J. et al. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med367, 2275–2283 (2012).
16. Zareba, W. et al. Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators: The RAID Trial. J Am Coll Cardiol72, 636–645 (2018).
17. Di Lullo, L. et al. Chronic kidney disease and cardiovascular complications. Heart Fail Rev20, 259–272 (2015).
18. Webster, G. et al. Cardiac Evaluation of Children With a Family History of Sudden Death. J Am Coll Cardiol74, 759–770 (2019).
19. Norrish, G. et al. Risk factors for sudden cardiac death in childhood hypertrophic cardiomyopathy: A systematic review and meta-analysis. Eur J Prev Cardiol24, 1220–1230 (2017).
20. Kenchaiah, S. et al. Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation116, 627–636 (2007).
21. de Sousa, M. R., Morillo, C. A., Rabelo, F. T., Nogueira Filho, A. M. & Ribeiro, A. L. P. Non-sustained ventricular tachycardia as a predictor of sudden cardiac death in patients with left ventricular dysfunction: a meta-analysis. Eur J Heart Fail10, 1007–1014 (2008).
22. Bilchick, K. C. et al. Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators. J Am Coll Cardiol69, 2606–2618 (2017).
23. Scheurlen, C. et al. ICD therapy in the elderly: a retrospective single-center analysis of mortality. Herzschr Elektrophys (2021) doi:10.1007/s00399-021-00742-x.
24. Pellegrini, C. N. et al. Impact of advanced age on survival in patients with implantable cardioverter defibrillators. Europace10, 1296–1301 (2008).
25. Krahn, A. D., Connolly, S. J., Roberts, R. S., Gent, M., & ATMA Investigators. Diminishing proportional risk of sudden death with advancing age: implications for prevention of sudden death. Am Heart J147, 837–840 (2004).
26. Pun, P. H. et al. Primary prevention implantable cardioverter defibrillators in end-stage kidney disease patients on dialysis: a matched cohort study. Nephrol Dial Transplant30, 829–835 (2015).
27. Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E. & Hsu, C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med351, 1296–1305 (2004).